This study is testing anifrolumab, given as a shot under the skin, to see if it's safe and effective for adults with moderate to severe polymyositis (PM) or dermatomyositis (DM). You would receive either anifrolumab or a placebo (an inactive substance) for 52 weeks, in addition to your usual care. After that, everyone will receive open-label anifrolumab for another 52 weeks. Researchers will measure how much your symptoms improve using a score called the Total Improvement Score (TIS) after 52 weeks. The study plans to enroll 240 participants, aged 18 to 75, who have a confirmed diagnosis of PM or DM. The current recruitment status is unclear.

Study design

This is a multicenter, randomized, placebo-controlled, and double-blind study, meaning participants are randomly assigned to a treatment group and neither you nor your doctor will know which treatment you are receiving initially. The study plans to enroll 240 participants.

What's involved

You would receive weekly subcutaneous (under the skin) injections for 52 weeks, followed by another 52 weeks of open-label injections.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 52 weeks, and participants will continue to receive treatment for an additional 52 weeks after that.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.